RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies

Clinical trial NCT07113496 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07113496
Sponsor: The First Affiliated Hospital with Nanjing Medical University
Status: NOT_YET_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Relapsed or Refractory B-cell Hematologic Malignancies B-cell Acute Lymphoblastic Leukemia (B-ALL)Multiple Myeloma (MM)Plasmablastic Lymphoma Relapsed or Refractory CD19+/BCMA+ Hematologic Malignancies Mature B-Cell Lymphoma

Start date: 2025-08-01
Primary completion: 2027-08-01
Enrollment: 27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.